A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Many medical treatments for ASDs have been proposed and studied, but there is currently no consensus regarding which interventions are most effective. OBJECTIVE: To systematically review evidence regarding medical treatments for children aged 12 years and younger with ASDs. METHODS: We searched the Medline, PsycInfo, and ERIC (Education Resources Information Center) databases from 2000 to May 2010, regulatory data for approved medications, and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Studies of secretin were not included in this review. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria. RESULTS: Evidence supports the benefit of risperidone and aripiprazole for challenging and repetitive behaviors in children with ASDs. Evidence also supports significant adverse effects of these medications. Insufficient strength of evidence is present to evaluate the benefits or adverse effects for any other medical treatments for ASDs, including serotonin-reuptake inhibitors and stimulant medications. CONCLUSIONS: Although many children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support benefit for most treatments. Risperidone and aripiprazole have shown benefit for challenging and repetitive behaviors, but associated adverse effects limit their use to patients with severe impairment or risk of injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“citalopram has demonstrated poor tolerability and no benefit for repetitive behaviour in children with ASD 208 .”
From Autism spectrum disorder (2020) · cites this paper as [208]
In the citing paper
“Although these drugs serve to manage challenging and repetitive behaviors, they have little effect on the social communication deficit observed in ASD 88 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [88]
In the citing paper
“These two agents, Risperdal and Abilify (11), do not target the core symptoms, but rather treat a cluster of associated symptoms referred to as irritability.”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Therefore, therapeutic efficacy is currently evaluated by improvement in the diagnostic behavioral symptoms (11, 50, 95).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Dysfunction in the dopamine system in ASD has been suggested, based on the beneficial effects of dopamine receptor antagonists (for example, antipsychotic drugs such as risperidone) in treating certain symptoms commonly exhibited by affected individuals, such as stereotypies, aggression, hyperactivity, and self-injury [123].”
From Social “wanting” dysfunction in autism: neurobiological underpinnings and treatment implications (2012) · cites this paper as [123]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Educating Children with Autism
Lord, C. (2001) · Cited by 1,499
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Cited by
Items 301–355 of 355
Pervin, M. M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9684 · Cited by 1
López, V. H., & Osorio, M. D. P. P. (2015) · Repositorio Institucional E-DocUR (Universidad Del Rosario) · doi:10.48713/10336_10227
Heitzer, A. M., Job, M. A., Pandit, N. K., & Valdovinos, M. G. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.324 · Cited by 1
From the Editor The Human Condition in the Twenty-First Century 439
Lee, C. M., & Brendel, D. H. (2012)
Biomedical Complementary Treatment Approaches
Hendren, R. L. (2013)
UNIVERSIDADE CATÓLICA PORTUGUESA CENTRO REGIONAL DAS BEIRAS
Saúde, D. D. C. D. (2012)
5HT2A Receptor Antagonist Treatment for Repetitive Behaviors and Restricted Interests in BTBR Mice
Amodeo, D. A. (2015) · Figshare
Trastornos del espectro autista. Puesta al día (II): diagnóstico y tratamiento
Fernández-Mayoralas, M. C., Al, F.-P., & Fernández‐Jaén, A. (2013) · Acta pediátrica española/Acta pediátrica española · Cited by 2
Future Directions in Psychopharmacology of Autism Spectrum Disorder
Mankad, D., & Anagnostou, E. A. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814602167_0019
Tsheringla, S. (2017) · Current Medical Issues · doi:10.4103/0973-4651.200308
Colasanto, M. (2015) · TSpace (University of Toronto) · Cited by 2
Examining the Influence and Role of Pharmacogenetics among Children with Autism Spectrum Disorder
Shaker, N. (2017) · TopSCHOLAR (Western Kentucky University)
Prosser, S. J. K. (2014) · e-scholar@UOIT (University of Ontario Institute of Technology)
Goodwin, A. J. (2017) · TSpace (University of Toronto)
Medical Model Perspectives on Autism
Brock, S. E., Holly, E., Sisson, H., & Ybarra, A. (2013) · Oxford University Press eBooks · doi:10.1093/obo/9780199791231-0063
Essential Child and Adolescent Psychiatry and Substance Use Disorders for the Nonpsychiatrist
Weidle, B. (2018) · Springer eBooks · doi:10.1007/978-3-319-89488-1_3
Use of Memantine in Autism Spectrum Disorder: a Case Report
Schindzielorz, A., Melvin, K., Holroyd, S., & Melvin, K. E. (2018)
Bennett, M., Webster, A. A., Goodall, E., & Rowland, S. (2018) · Springer eBooks · doi:10.1007/978-981-13-3359-0_8
Treatments for Obsessive-Compulsive Disorder and Comorbid Disorders
Ivarsson, T., & Weidle, B. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108235655.022
Shindler, A. E., Hill‐Yardin, E. L., Petrovski, S., Bishop, N. E., & Franks, A. E. (2020) · Research in Autism · doi:10.1016/j.rasd.2020.101516
Autism: a curse on today’s society
Sarkar, S. (2020) · Journal of Applied Pharmaceutical Research · doi:10.18231/j.joapr.2019.v.8.i.1.001 · Cited by 2
Research Article The diagnosis of autism spectrum disorder in Nghe An province, Vietnam
Thuc, S. C., Thi, K. A. T., Ngoc, L. T. T., & Vinh, H. D. (2021) · Genetics and Molecular Research · doi:10.4238/gmr18736
自閉スペクトラム症 (ASD) 児の鎮静に際して必要な理解や配慮
Kurokami, T., & 加恵子, 小. (2021) · 脳と発達 · doi:10.11251/ojjscn.53.105 · Cited by 1
Neuropsychologie et remédiations des troubles du spectre de l’autisme
Bizet, É., & de la Rosa, S. M. (2018) · De Boeck Supérieur eBooks · doi:10.3917/dbu.breti.2018.01.0063
van Andel, D. M. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/943
Basics of Psychopharmacological Management
Chan, E., Trier, K. A., & Chung, P. J. (2018) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610021357-23
Chelly, J. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717992196.793473535
Spectrum of Neurodegeneration in Autism Spectrum Disorder
Rani, K. (2022) · IGI Global eBooks · doi:10.4018/978-1-6684-5360-5.ch019
Bibliography: Child and Adolescent Psychiatry: Life Cycle and Family
(2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.3.327
Novel Therapeutic Targets to Treat Social Behavior Deficits in Autism and Related Disorders
Gould, G. G. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada612531
(2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809480-8.00023-6
Complementary and Alternative Therapies
Guiot, C., Grasso, F., Rocchetti, M., & Brondino, N. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-030-88538-0_64
Monitoring Progress in Core Symptoms of Autism Spectrum Disorder
Callahan, M., Matson, J. L., & Brown, M. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-030-88538-0_15
Neurobiological Bases of Autism
Shehata, G. A. (2021) · Psychology & Psychological Research International Journal · doi:10.23880/pprij-16000283
Mu-Suppression Neurofeedback Training Targeting the Mirror Neuron System: A Pilot StudyPreprint
Dastgheib, S. S., Wang, W., Kaufmann, J. M., Moratti, S., & Schweinberger, S. R. (2023) · Research Square · doi:10.21203/rs.3.rs-3470259/v1
Application of Digital Therapy in Children with Autism Spectrum Disorder
李, 娜. (2023) · Advances in Psychology · doi:10.12677/ap.2023.1311655
(2016) · Wiley eBooks · doi:10.1002/9781394259472.refs
Behavioral analysis on children with Autism Spectrum Disorder
Thakur, M., & Chauhan, A. (2024) · Journal of Advances in Science and Technology · doi:10.29070/5cxw5a21 · Cited by 2
Hartley-McAndrew, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15682-3.00008-0
CUIDADOS DE ENFERMAGEM PRESTADO A CRIANÇAS COM TRANSTORNO DE ESPECTRO AUTISTA (TEA)
do Nascimento, A. L. D. C. P., Fochesato, M., dos Santos, K. P., Pinheiro, Y. V. F., Sousa, Y. D. C., & Véras, L. M. C. (2024) · Even3 Publicações eBooks · doi:10.29327/5433745.1-4
Psychopharmacology Considerations for Children Aged under 6 Years
Romanowicz, M., Pease, E. R., Tarikogullari, I., PON, N. C., & Gleason, M. M. (2025) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2024.08.003
The role of IGF-II in memory enhancement : implications for autism spectrum disorders
Kohtz, A. S. (2014) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/0vca-4kf0
de Moraes, F. C. A., Lôbo, A. D. O. M., Sano, V. K. T., Pereira, C. R. M., Leão, L. B. C., Carneiro, T. X., & Burbano, R. M. R. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2540401
“…to selection, comparability, and exposure criteria, a higher score on the NOS indicates a lower risk of bias and thus higher methodological quality, with scores typically interpreted as follows: 7–9 points representing good quality, 4–6 points fair quality, and 0–3 points poor quality [35,36].”
Lee, H., Trân, N. B., & Lee, S.-J. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1677851
“FDA-approved drugs, including risperidone and aripiprazole, improve behavioral disturbances but do not address core deficits or alter disease progression, and their long-term safety remains a concern (McPheeters et al., 2011; Owen et al., 2009).”
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., Leventhal, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · Figshare · doi:10.6084/m9.figshare.11978739
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., Leventhal, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · Figshare · doi:10.6084/m9.figshare.11978745
Psychotropic Medications as Treatments for People with Autism Spectrum Disorders
Li, A., Poling, A. D., & Ehrhardt, K. E. (2025) · Autism and child psychopathology series · doi:10.1007/978-3-032-01237-1_16
Rothärmel, M. (2019) · theses.fr (ABES) · doi:10.70675/e8883013z1f99z4729z9f22z3ebbd6f1586a · Cited by 2
Emotion dysregulation in autistic adults : an ecological, self-report, and physiological approach
Costache, M. E. (2024) · theses.fr (ABES) · doi:10.70675/575e0a4az1174z4c91z976cz320b40c5304a
WWOX in brain development and disease: Molecular mechanisms and therapeutic opportunities
Obeid, M., Wang, J., Abudiab, B., Akkawi, R., & Aqeilan, R. I. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107446 · Cited by 1
Novak, M. R. (2026) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2026.16.00655
Metadata
- Authors
- McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J.
- Affiliations
- Vanderbilt University (US)
- ORCID
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2011-05-01
- Volume
- 127
- Issue
- 5
- Pages
- e1312-e1321
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2121150539
- Cited by
- 356
- References
- 55
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 19 · 2021: 17 · 2020: 23 · 2019: 22 · 2018: 27 · 2017: 28 · 2016: 20 · 2015: 28 · 2014: 25 · 2013: 42 · 2012: 41
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- autism spectrum disorder, medical treatment, children, risperidone, aripiprazole, behavioral problems, repetitive behavior, adverse effects, serotonin reuptake inhibitors, stimulant medication, antipsychotic drugs, quality of evidence
- MeSH terms
- Aripiprazole, Child, Child Development Disorders, Pervasive, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Patient Compliance, Piperazines, Prognosis, Serotonin Antagonists, Severity of Illness Index, Antipsychotic Agents, Citalopram, Quinolones, Randomized Controlled Trials as Topic, Treatment Outcome, Risperidone, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.